Press Releases

Date Title and Summary Additional Formats
Toggle Summary CHF Solutions submits 510(k) application for Use of Aquadex FlexFlow® System with Pediatric Patients
EDEN PRAIRIE, Minn. , Oct. 01, 2019 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq:CHFS) today announced that it has submitted an application to the FDA requesting for 510(k) clearance of the Aquadex FlexFlow system to include pediatric patients who weigh 20kg or more.
View HTML
Toggle Summary Multi-Center, Retrospective Study Evaluates Use of Ultrafiltration Therapy with Aquadex FlexFlow® System in Pediatric Patients
EDEN PRAIRIE, Minn. , Sept. 24, 2019 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq:CHFS) today announced the publication of a multi-center, retrospective study in the Clinical Journal of the American Society of Nephrology 1 evaluating the use of hemofiltration and ultrafiltration therapy with the
View HTML
Toggle Summary CHF Solutions, Inc. to Present at the Ladenburg Thalmann’s 2019 Healthcare Conference on September 24, 2019
EDEN PRAIRIE, Minn. , Sept. 19, 2019 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq:CHFS) today announced that Claudia Napal Drayton , the company’s CFO, will be presenting and meeting with investors at the 2019 Landenburg Thalmann’s 2019 Healthcare Conference on September 24, 2019 at 4:00 PM ET
View HTML
Toggle Summary CHF Solutions, Inc. to Host a Call with Investigator Panel to Discuss Results of a Study Involving Use of Aquadex FlexFlow® in Pediatric Patients on September 25, 2019
EDEN PRAIRIE, Minn. , Sept. 17, 2019 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ: CHFS) announced today that it will host a conference call and webcast at 1:00 PM ET on Wednesday, September 25, 2019 to discuss the results of a multicenter, retrospective study involving pediatric patients who
View HTML
Toggle Summary CHF Solutions, Inc. to Exhibit at the 23rd Annual Scientific Meeting of the Heart Failure Society of America
EDEN PRAIRIE, Minn. , Sept. 10, 2019 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq:CHFS) today announced it would be exhibiting at the 23 rd Annual Scientific Meeting of the Heart Failure Society of America from September 14-16, 2019 . The conference is being held at the Pennsylvania Convention
View HTML
Toggle Summary CHF Solutions, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EDEN PRAIRIE, Minn. , Sept. 06, 2019 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ: CHFS), today announced that, on September 3, 2019 , the independent directors approved four equity awards under CHF Solution’s New-Hire Equity Incentive Plan, as material inducements to four individuals entering
View HTML
Toggle Summary CHF Solutions, Inc. Appoints World-Renowned Heart Failure Cardiologist, Maria Rosa Costanzo, M.D. to Company’s Board of Directors
EDEN PRAIRIE, Minn. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq:CHFS) today announced that Maria Rosa Costanzo , M.D. has been appointed to the Company's Board of Directors. Dr. Costanzo is the medical director, Heart Failure Research , at Advocate Heart Institute , and the
View HTML
Toggle Summary CHF Solutions, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EDEN PRAIRIE, Minn. , Aug. 16, 2019 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ: CHFS), today announced that, on August 15, 2019 , the independent directors approved nine equity awards under CHF Solution’s New-Hire Equity Incentive Plan, as material inducements to nine individuals entering into
View HTML
Toggle Summary New Publication Highlights Transient Increases in Creatinine or Tubular Injury Markers in Heart Failure Patients Should Not Dissuade Use of Ultrafiltration
EDEN PRAIRIE, Minn. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- CHF Solutions , Inc. (Nasdaq: CHFS) announced today the publication of a study in Circulation Heart Failure 1 highlighting the benefits of decongestion outweigh concerns from previous studies that showed a rise in creatinine levels or tubular
View HTML
Toggle Summary CHF Solutions, Inc. Announces 53 Percent Increase in Revenues for Second Quarter 2019 Over Previous Year and 38 Percent Increase from Q1 2019
EDEN PRAIRIE, Minn. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS), a medical device company focused on developing, manufacturing and commercializing a clinically proven alternative to diuretics for the treatment of fluid overload,  announced today its results for the second
View HTML